Notable
LAM-001 · Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Primary completion pushed from Jul 16, 2027 to Mar 2028
Also in this update: Trial sites expanded: 3 → 32 locations; Study completion pushed from Aug 30, 2028 to Feb 2029; and 1 more change in the last 30 days
IRulya Therapeutics Inc.Phase 2 NCT05798923 Registry history of NCT05798923 on ClinicalTrials.gov (opens the registry)